Filing Flows › Hyperfine (HYPR) › Who owns the stock
Who owns Hyperfine (HYPR) stock
81 funds reported Hyperfine (HYPR) shares in their latest 13F filings, worth $32.2M in all. The largest holder is BlackRock ($6.3M). Last quarter 50 funds added to their stakes and 15 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| BlackRock | 4,673,087 | $6.3M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 3,380,087 | $4.6M | decrease | 2026-06-30 |
| Vanguard Group | 3,568,038 | $3.5M | increase | 2025-12-31 |
| Geode Capital Management, LLC | 1,960,811 | $2.6M | increase | 2026-06-30 |
| Fosun International | 1,742,020 | $2.4M | unchanged | 2026-06-30 |
| Catalio Capital Management, LP | 1,320,041 | $1.8M | unchanged | 2026-06-30 |
| State Street | 1,016,970 | $1.4M | increase | 2026-06-30 |
| Renaissance Technologies LLC | 945,836 | $1.3M | increase | 2026-06-30 |
| Alphabet | 898,720 | $1.2M | unchanged | 2026-06-30 |
| Northern Trust | 633,054 | $855K | increase | 2026-06-30 |
| Vanguard Fiduciary Trust | 567,109 | $766K | increase | 2026-06-30 |
| Vanguard Portfolio Management LLC | 547,200 | $739K | new | 2026-06-30 |
| Marshall Wace, LLP | 342,116 | $462K | new | 2026-06-30 |
| Two Sigma Investments, LP | 325,999 | $440K | new | 2026-06-30 |
| Bank of New York Mellon | 310,405 | $419K | increase | 2026-06-30 |
Hyperfine's latest quarter
Hyperfine, Q2 2026: revenue $3.9M (+45% year over year), operating margin -216.9%, net loss $9.3M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most HYPR stock?
By the latest 13F filings: BlackRock ($6.3M); Vanguard Capital Management LLC ($4.6M); Vanguard Group ($3.5M); Geode Capital Management, LLC ($2.6M); Fosun International ($2.4M).
What is the short interest in HYPR?
3,774,668 shares were sold short at the 2026-10-15 settlement, -3.25% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.